HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: NTP Disperse Blue 1 carcinogen listing

This article was originally published in The Rose Sheet

Executive Summary

NTP Disperse Blue 1 carcinogen listing: National Toxicology Program to include Disperse Blue 1 in its Eighth Biennial Report on Carcinogens, a Congressionally mandated listing of known human carcinogens and reasonably anticipated carcinogens, NTP announced in an April 30 Federal Register notice. The ingredient, which is used in four coal tar hair dye products, according to FDA data, is "reasonably anticipated" to be a carcinogen, NTP states. The Cosmetic Ingredient Review expert panel reviewed the ingredient in 1994 and determined it safe when used in concentrations less than 1%. At the time of its review, CIR considered carcinogenicity data for rats, and noted that the tests involved ingestion of the ingredient and had caused a species of tumor that has not been reported in humans. The panel added that review of data for topically applied Disperse Blue 1 showed no carcinogenic link...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS004112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel